



**Neuren (NEU) – ASX Announcement**

**10 June 2021**

## **Update – Annual Meeting of Shareholders, 22 June 2021**

**Melbourne, Australia:** Neuren Pharmaceuticals Limited (ASX: NEU) advises that its Annual Meeting of Shareholders scheduled for 2:30pm on Tuesday 22 June 2021, which was planned to be a physical and virtual meeting, will now proceed as a virtual meeting only. This follows the recent announcement by the Victorian Department of Health and Human Services about COVID restrictions to take effect from 11:59pm, 10 June 2021, including limits on public gatherings and masks being required for all indoor gatherings. In the interests of public health and due to continued uncertainty, Neuren has determined that it is not feasible to plan for shareholders to attend in person. All shareholders are encouraged to attend the Meeting online.

As stated in the Notice of Meeting published on 21 May 2021, the Meeting can be attended online via the following link:

<https://agmlive.link/NEU21>

An online meeting guide and the Notice of Meeting are available on the Neuren website at:

<https://www.neurenpharma.com/irm/content/asx-announcements.aspx?RID=8>

### **About Neuren**

Neuren is developing two new drug therapies to treat multiple serious neurological disorders that emerge in early childhood, none of which have any approved medicines.

The lead drug compound, trofinetide, is currently in a Phase 3 clinical trial for Rett syndrome with top-line results expected in Q4 2021 and has completed a Phase 2 clinical trial in Fragile X syndrome. Both programs have been granted Fast Track designation by the US Food and Drug Administration (FDA). Neuren has granted an exclusive licence to ACADIA Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America.

Neuren plans to initiate Phase 2 trials of its second drug candidate, NNZ-2591, for each of Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome in H2 2021. Neuren is also preparing for a Phase 2 trial in Prader-Willi syndrome.

Because of the urgent unmet need, five programs have been granted “orphan drug” designation in both the United States and the European Union, a designation that provides incentives to encourage therapies for rare and serious diseases.



**Contact:**

Lauren Frazer, Company Secretary: [lfrazer@neurenpharma.com](mailto:lfrazer@neurenpharma.com); +61 417 016 599

***Forward-looking Statements***

*This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.*

**ASX Listing Rules information**

This announcement was authorized to be given to the ASX by the CEO of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124